相关实验视频
Updated: Jun 22, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
蛋白酸酶2A抑制和检查点免疫治疗的组合:一个完美的风暴
Mary C Clark1,2, Rongze Olivia Lu3,4, Winson S Ho3
1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA.
抑制蛋白酸酶2A (PP2A) 可能通过增加瘤抗原表达和T细胞活性来增强癌症免疫疗法. 这种方法有望改善对免疫检查点阻塞疗法的反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 免疫检查点阻塞 (ICB) 是一种强大的癌症疗法,但患者的有限反应需要组合策略.
- 蛋白酸酶2A (PP2A) 在与癌症免疫相关的细胞信号通路中起着关键作用.
研究的目的:
- 研究抑制PP2A的潜力,以提高ICB和其他T细胞介导癌症疗法的疗效.
- 探索PP2A抑制影响抗瘤免疫力的机制.
主要方法:
- 使用临床前癌症模型来评估PP2A抑制的影响.
- 分析分子通路,包括新抗原表达和cGAS/STING通路.
- 对T细胞反应的评估,包括调控性T细胞抑制和细胞毒性T细胞激活.
主要成果:
- 发现PP2A抑制会增加瘤新抗原的表达,并激活cGAS/STING通路.
- 观察到抑制调节性T细胞和增强的细胞毒性T细胞激活.
- 在临床前研究中,PP2A抑制与ICB协同作用,患者数据表明,在具有PP2A突变的瘤中,ICB反应得到改善.
结论:
- 抑制PP2A是一种有前途的策略,可以使瘤对ICB和T细胞治疗产生敏感性.
- 向PP2A可能会克服耐药性机制,并扩大受益于当前免疫疗法的患者人群.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
09:01Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity